501 related articles for article (PubMed ID: 33906189)
1. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
[TBL] [Abstract][Full Text] [Related]
3. Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival.
Shimose S; Iwamoto H; Tanaka M; Niizeki T; Shirono T; Kajiwara A; Noda Y; Kamachi N; Okamura S; Nakano M; Kuromatsu R; Kawaguchi T; Koga H; Torimura T
Oncology; 2021; 99(12):756-765. PubMed ID: 34518483
[TBL] [Abstract][Full Text] [Related]
4. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.
Lee TY; Lin CC; Chen CY; Wang TE; Lo GH; Chang CS; Chao Y
Medicine (Baltimore); 2017 Sep; 96(37):e7655. PubMed ID: 28906355
[TBL] [Abstract][Full Text] [Related]
5. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
[TBL] [Abstract][Full Text] [Related]
6. Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Itobayashi E; Nouso K; Kariyama K; Ishikawa T; Hirooka M; Hiasa Y
Cancer Sci; 2017 Jul; 108(7):1414-1420. PubMed ID: 28406546
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
8. Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):261-268. PubMed ID: 32282541
[TBL] [Abstract][Full Text] [Related]
9. Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.
Ha Y; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS; Park SR; Ryu MH; Ryoo BY; Kang YK; Kim KM
Oncotarget; 2016 Nov; 7(45):74303-74313. PubMed ID: 27494871
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
12. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
14. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Hiraoka A; Kumada T; Kariyama K; Tada T; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
J Gastroenterol Hepatol; 2021 Jul; 36(7):1812-1819. PubMed ID: 33171524
[TBL] [Abstract][Full Text] [Related]
15. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
[TBL] [Abstract][Full Text] [Related]
16. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
17. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
18. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
19. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries.
Sanoff HK; Chang Y; Stavas JM; Stürmer T; Lund J
J Natl Compr Canc Netw; 2015 Sep; 13(9):1102-10. PubMed ID: 26358794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
